Group 1 - The core viewpoint of the news is that Chengda Biological experienced a decline in stock price and trading volume, with significant financing activities indicating high investor interest despite recent financial challenges [1][2]. Group 2 - On December 23, Chengda Biological's stock fell by 0.84%, with a trading volume of 32.51 million yuan. The financing buy-in amount was 4.22 million yuan, while the financing repayment was 2.56 million yuan, resulting in a net financing buy of 1.67 million yuan [1]. - As of December 23, the total balance of margin trading for Chengda Biological was 272 million yuan, with the financing balance accounting for 2.51% of the circulating market value, indicating a high level compared to the past year [1]. - In terms of securities lending, on December 23, 5,971 shares were repaid, and 1,200 shares were sold short, with a selling amount of 31,100 yuan. The remaining short-selling volume was 43,300 shares, with a balance of 1.12 million yuan, also at a high level compared to the past year [1]. Group 3 - As of September 30, the number of shareholders for Chengda Biological was 24,300, a decrease of 4.17% from the previous period, while the average circulating shares per person increased by 4.36% to 17,147 shares [2]. - For the period from January to September 2025, Chengda Biological reported operating revenue of 1.096 billion yuan, a year-on-year decrease of 15.88%, and a net profit attributable to shareholders of 165 million yuan, down 50.01% year-on-year [2]. - Since its A-share listing, Chengda Biological has distributed a total of 1.492 billion yuan in dividends, with 1.075 billion yuan distributed over the past three years [2]. Group 4 - As of September 30, among the top ten circulating shareholders, Hong Kong Central Clearing Limited was the fourth largest with 1.9124 million shares, an increase of 9,100 shares from the previous period. Meanwhile, Southern CSI 1000 ETF held 1.9011 million shares, a decrease of 7,600 shares [2].

Core Viewpoint - Chengda Biological has terminated six vaccine research and development projects since early December, including five under the "Human Vaccine R&D Project" and one under the "Biotechnology Product R&D Production Base Project" due to market dynamics and technical feasibility assessments [1][2]. Group 1: Project Termination - The company announced the termination of the "b-type influenza Haemophilus influenzae type b conjugate vaccine" development project and five other sub-projects, including the pentavalent rotavirus vaccine, due to a lack of commercial viability and feasibility [1][2]. - The total planned investment for the "Human Vaccine R&D Project" was 837 million yuan, fully funded by raised capital, focusing on multi-valent and innovative vaccines [1]. Group 2: Market Competition - The pentavalent rotavirus vaccine, previously a key focus, faces intense competition with the successful launch of the world's first hexavalent rotavirus vaccine by China National Pharmaceutical Group, leading to a reassessment of its commercial potential [2]. - The domestic rabies vaccine market has become increasingly competitive, with 23 marketed products and 19 in clinical development, impacting Chengda Biological's market share significantly [3]. Group 3: Financial Performance - Chengda Biological's revenue has declined over the past three years, with reported revenues of 1.815 billion yuan, 1.750 billion yuan, and 1.675 billion yuan, reflecting year-on-year decreases of 13.08%, 3.58%, and 4.22% respectively [3]. - For the first three quarters of 2025, the company reported revenues of 1.096 billion yuan, a year-on-year decline of 15.88%, and a net profit of 165 million yuan, down 50.01% [4].

中信证券股份有限公司 关于辽宁成大生物股份有限公司 部分募集资金投资项目内部投资结构调整 的核查意见 中信证券股份有限公司（以下简称"保荐机构"或"中信证券"）作为辽宁成大 生物股份有限公司（以下简称"成大生物"或"公司"）首次公开发行股票并在科创 板上市的持续督导保荐机构，根据《上海证券交易所科创板上市公司自律监管指 引第 1 号——规范运作》《上市公司募集资金监管规则》等有关规定，对公司 部分募集资金投资项目内部投资结构调整的事项进行了核查，具体情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会出具的《关于同意辽宁成大生物股份有限公司 首次公开发行股票注册的批复》（证监许可〔2021〕3019号），公司首次公开发 行人民币普通股（A股）4,165万股，每股发行价格为110.00元，募集资金总额为 人民币458,150.00万元；扣除各项发行费用后，实际募集资金净额为人民币 434,137.94万元。其中，募投项目拟投入资金204,000.00万元，超募资金为 230,137.94万元。上述募集资金已于2021年10月25日全部到位，由容诚会计师事 务所（特殊普通合伙）对本次发行募集资金的到账情况 ...

证券日报网讯 12月18日晚间，成大生物发布公告称，公司于2025年12月18日召开第五届董事会第二十 五次会议，审议并通过了《关于部分募集资金投资项目内部投资结构调整的议案》，同意公司根据募投 项目实施的需要对部分募投项目的内部投资结构进行调整。本次事项尚需提交股东会审议。 （文章来源：证券日报） ...

证券代码：688739 证券简称：成大生物 公告编号：2025-060 辽宁成大生物股份有限公司 关于部分募集资金投资项目内部投资结构调整的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 部分募投项目内部投资结构调整情况：为进一步优化募集资金使用效率， 合理配置资源，辽宁成大生物股份有限公司（以下简称"公司"）拟对部分募集 资金投资项目（以下简称"募投项目"）的内部投资结构进行调整。本次募投项 目内部投资结构调整包含两项内容：一是公司拟终止"人用疫苗研发项目"项下 子项目"b 型流感嗜血杆菌结合疫苗"（以下简称"hib 疫苗"）的开发；二是 针对"生物技术产品研发生产基地项目"内部投资结构及具体金额进行优化调 整，以匹配项目建设节奏与实际需求。本次调整为募投项目内部层面的投资结构 优化，不涉及募投项目投资总额、实施主体及实施地点的变更，调整后可保障相 关项目规范有序推进，与公司整体发展战略高度契合。 公司于 2025 年 12 月 18 日召开第五届董事会第二十五次会议，审议并通过 了《关于部分募集资金投 ...

辽宁成大生物股份有限公司 关于2025年第二次临时股东会增加临时提案暨延期 召开的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股东会增加临时提案《关于部分募集资金投资项目内部投资结构调 整的议案》。 证券代码：688739 证券简称：成大生物 公告编号：2025-061 1、原股东会的类型和届次： 2025年第二次临时股东会 | 股份类别 | 股票代码 | 股票简称 | 股权登记日 | | --- | --- | --- | --- | | A 股 | 688739 | 成大生物 | 2025/12/16 | 二、股东会增加临时提案及延期召开的原因 1、提案人：辽宁成大股份有限公司（以下简称"辽宁成大"）。 2、提案程序说明：公司已于 2025 年 12 月 6 日披露《关于召开 2025 年第二 次临时股东会的通知》。2025 年 12 月 17 日，公司董事会收到控股股东辽宁成大 （直接持股比例 54.67%）提交的书面函件《关于向辽宁成大生物股份有限公司 提请增加 2025 年第二次临时股 ...

人民财讯12月18日电，成大生物(688739)12月18日公告，公司拟对部分募集资金投资项目的内部投资结 构进行调整。本次募投项目内部投资结构调整包含两项内容：一是公司拟终止"人用疫苗研发项目"项下 子项目"b型流感嗜血杆菌结合疫苗"（简称"hib疫苗"）的开发；二是针对"生物技术产品研发生产基地项 目"内部投资结构及具体金额进行优化调整，以匹配项目建设节奏与实际需求。 ...

"辽宁成大有着进取创新的基因，现在要做的就是扫清发展障碍，让这份活力重新迸发。"近日，辽宁成 大董事长徐飚接受上海证券报记者采访，分享了公司最新动向和发展规划。 2 2 4 x 1 Erica "年初的董事会换届不是简单的控股股东变化，而是各方股东的共识凝聚。"徐飚表示，目前粤民投在辽 宁成大的持股比例约为16%，此次换届获得了辽宁国资、广西鑫益信、吉林敖东等持股5%以上股东的 全力支持。 深入梳理辽宁成大新一届董事会及高管团队新成员的履历可见，粤民投选派了具备风控合规专业背景与 资深投行从业经验的人才履职，为上市公司后续的可持续发展注入坚实支撑。 "在辽宁成大的关键经营事项上，粤民投、辽宁国资等核心股东的观念始终保持高度一致。"徐飚表示， 作为投资控股型的上市公司，辽宁成大拥有稳健可持续的资产负债结构非常重要，因此管理层坚定推进 降杠杆举措。 今年前三季度扣非后归母净利润同比增长92.20%，总资产较年初增长2.79%，资产负债率同比下降1.98 个百分点——今年10月底，辽宁成大交出一份盈利能力提升、资产结构向好的"成绩单"。 数据的背后，是辽宁成大在治理重塑、债务优化等领域的系统性发力。今年初，辽宁成大 ...

（文章来源：证券日报） 证券日报网讯 12月5日晚间，成大生物发布公告称，公司拟续聘致同会计师事务所（特殊普通合伙）为 2025年度财务报告及内部控制审计机构，审计费用总额不超过70万元，其中财务审计费用55万元、内控 审计费用15万元，与2024年度持平，该事项尚需12月23日股东会审议通过。 ...

Core Viewpoint - The company, Liaoning Chengda Biological Co., Ltd., is convening its second extraordinary general meeting of shareholders in 2025 to discuss adjustments to its fundraising projects and internal investment structure, including the termination of certain research projects and the allocation of funds to new initiatives [1][18]. Meeting Details - The second extraordinary general meeting of shareholders will be held on December 23, 2025, at 9:30 AM in Shenyang, Liaoning Province [4]. - The meeting will utilize a combination of on-site and online voting methods, with specific time slots for voting [2][6]. Fundraising Project Adjustments - The company plans to optimize the internal investment structure of its "Human Vaccine Research Project" by terminating five research sub-projects and reallocating unused funds to other ongoing and new sub-projects, specifically the "High-Value Pneumococcal Polysaccharide Conjugate Vaccine" and "High-Dose Influenza Virus Split Vaccine" [19][30]. - A total of 100 million yuan will be specifically allocated to increase capital in its wholly-owned subsidiary, Chengda Biological (Benxi) Co., Ltd., to support the implementation of the "High-Dose Influenza Virus Split Vaccine" [19][43]. Project Timeline Extensions - The fundraising usage period for the "Human Vaccine Research Project" and "Biotechnology Product R&D Production Base Project" has been extended to December 2028 to adapt to global macroeconomic changes and industry trends [20][46]. - The adjustments made will not affect the total planned investment amount for the "Human Vaccine Research Project" [41]. Financial Management and Compliance - The company has established a special account for the management of the raised funds, ensuring that all funds are used specifically for the designated projects [45]. - The adjustments and extensions have been approved by the company's board and will be submitted for shareholder approval at the upcoming meeting [25][46].